A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with ...

Researchers from Simon Fraser University have unveiled an artificial intelligence framework that could transform drug ...

An update from Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) is now available. Shanghai Henlius Biotech, Inc. announced that its New Drug ...

Cognition Therapeutics shares rose 30% pre-market after the FDA confirmed its Phase 3 trial for Alzheimer's drug Zervimesine.

Indoco Remedies receives US FDA final approval for rivaroxaban tablets USP, 2.5 mg, 10 mg, 15 mg and 20 mg: Our Bureau, Mumbai Wednesday, August 13, 2025, 13:45 Hrs [IST] Indoco R ...

A new FDA program will use a two-phase approach to help boost domestic drug manufacturing, while OpenAI is leaning into health care with the launch of GPT-5.

Net loss (GAAP) widened year over year for the six months ended Q2 2025, driven by sharply higher research and administrative expenses. Revenue (GAAP) fell 31.0% year-over-year for the six months ...

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and ...

Researchers at the Optics and Photonics Research Center (CePOF) have succeeded in increasing the susceptibility of the fungus ...

Dr. Aaron Gerds explained when treatment with rusfertide will become accessible for patients with a myeloproliferative neoplasm like polycythemia vera.

StayModern reports there are five industries ripe for AI disruption: healthcare, finance, retail, legal, and manufacturing.

Senores Pharmaceuticals acquires two ANDAs from Teva Pharmaceuticals USA Inc., expanding its US market presence.